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Cardiovascular disease, specifically ischae ­
mic heart disease (IHD), is the main cause 
of death in developed countries, as cited 
by a 2018 World Health Organization 
(WHO) report.[1] According to Statistics 
South Africa (Stats SA),[2] the main con­
tributors to mortality in SA in 2016 
were disorders of the circulatory sys­
tem (18.5%), followed by communicable 
diseases (18.2%). When evaluating the 
trend in mortality rates since 2013, it was 
found that deaths due to communicable 
diseases saw a 3% decline (from 22.5%), 
while disorders of the circulatory system 
saw a 1.1% increase in deaths in 2015. 
These figures confirm the findings of the 
report[2] that there is an epidemiological 
shift away from communicable diseases 
towards non­communicable diseases.
In the report by Stats SA,[2] IHD was found 
to be the third most common natural cause 
of death (6.0%) in Western Cape Province, 
SA, overshadowed only by diabetes mellitus 
(7.7%) and HIV (6.2%).
ST­segment elevation myocardial infarction 
(STEMI) contributes significantly to the 
burden of IHD, and timeous treatment 
of patients can reduce morbidity and 
mortality. Primary percutaneous coronary 
intervention (PCI) is the preferred strategy 
for the treatment of acute STEMI. If primary 
PCI is not available, the alternative strategy 
is to administer a fibrinolytic agent to break 
down the occlusive thrombus and potentially 
reperfuse viable myocardium, allowing time 
for transfer to a PCI centre. The ISIS­2 
study[3] found that timeous fibrinolysis led 
to preservation of left ventricle function by 
reducing cardiac remodelling. The Division 
of Cardiology at Tygerberg Hospital, Cape 
Town, SA follows the guidelines set out 
by the European Society of Cardiology 
(ESC), which recommends administration 
of a fibrinolytic agent within 10 minutes of 
a STEMI diagnosis if PCI is not available 
within 60 ­ 90 minutes (the pharmaco-invasive 
strategy), followed by referral to a PCI 
centre.[4]
The total time of ischaemia can be divided 
into the following intervals (Fig. 1):
1. between symptom onset and presentation 
at a healthcare centre (transport delay) 
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Background. ST­segment elevation myocardial infarction (STEMI) is one of the main contributors to morbidity and mortality in South 
Africa (SA). Timeous intervention by means of percutaneous coronary intervention (PCI) or fibrinolysis can significantly improve the 
outcome of STEMI.
Objectives. To determine the median time interval between diagnosis and fibrinolysis in patients presenting to centres within the drainage 
area of Tygerberg Hospital, Cape Town, SA, and compare it with the European Society of Cardiology (ESC) recommendation of 10 minutes. 
Methods. A retrospective medical record review of patients presenting to the abovementioned centres between 1 March 2017 and 
28 February 2018 was performed. The primary presenting centre, time between diagnosis and fibrinolysis and discharge medication were 
recorded, in addition to other relevant demographic information.
Results. A total of 492 patients were identified, of whom 447 were included in the study. Three hundred and eighteen patients received 
fibrinolysis, of whom 18 (5.7%) were treated within 10 minutes of diagnosis. The median time interval between diagnosis and fibrinolysis 
was 67 (interquartile range (IQR) 32.5 ­ 122.5) minutes.
Conclusions. Most patients received fibrinolysis >10 minutes after diagnosis, which indicates suboptimal therapy when compared with the 
ESC guidelines. Future studies should investigate the factors prolonging this therapeutic delay.
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Fig. 1. Time intervals between symptom onset and fibrinolysis. (ER = emergency room; ECG = electro-
cardiogram.)
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2. between presentation and diagnosis of STEMI (diagnostic delay)
3. between STEMI diagnosis and treatment (treatment delay).
The time between symptom onset and diagnosis can be influenced by 
a multitude of factors, including recognition of symptoms, transport, 
as well as access to a healthcare facility. The time between diagnosis 
and treatment, however, is largely influenced by the competency and 
efficacy of healthcare staff and can be targeted for improvement if it 
does not meet guideline­recommended standards. Maximal effect 
of fibrinolysis is seen when it is administered within 60 minutes of 
symptom onset.[5] According to a study by Maharaj et al.,[6] fibrinolysis 
is most commonly delayed by the attending doctor seeking advice from 
senior staff members, difficulties in interpreting the electrocardiogram 
(ECG) and patients presenting with atypical symptoms.
SA healthcare setting 
Healthcare in SA is comprised of a publicly and privately funded 
system. The former consists of facilities and staff provided by the 
National Department of Health, while patients can also opt to be 
treated in privately funded facilities. A high percentage (84%) of SA 
citizens make use of publicly funded healthcare,[7] highlighting the 
burden placed on these settings.
Tygerberg Hospital is a tertiary academic centre that provides 
a PCI service to a drainage area spanning large parts of the 
Western Cape. The geographical distances, coupled with an often­
overburdened ambulance service, lead to transfer times of >90 min­
utes in most cases. Therefore, the vast majority of STEMI patients are 
treated initially with a fibrinolytic agent. This emphasises the need 
for efficient prereferral STEMI treatment. While the ESC STEMI 
guidelines state a treatment target of 10 minutes, it is anecdotally 
evident that this target is seldom achieved. We hypothesised that most 
patients presenting with STEMI are not administered a fibrinolytic 
agent within 10 minutes, and therefore structured this study to see 
if this is the case.
Objectives
The primary aim of this study was to evaluate the time (minutes) 
between the diagnosis of STEMI and the administration of a 
fibrinolytic agent. By recording either the time of the diagnostic ECG, 
or the time of diagnosis as stated by the involved medical doctor, as 
well as the time of fibrinolysis, we could calculate a mean among our 
study population and compare that with the proposed standard of 
care. Making use of statistical analysis, we represent these data as a 
mean duration (minutes), with a 95% confidence interval (CI) and a 
standard deviation (SD) from the mean.
A secondary objective was to assess whether appropriate secondary 
prevention medication was prescribed on discharge.
Methods
Participants and setting
Tygerberg Hospital is one of two tertiary hospitals in the Western 
Cape and serves as the referral centre for STEMI patients presenting 
to peripheral hospitals within a demarcated drainage area. On transfer, 
these patients are admitted to a dedicated cardiology ward, consisting 
of an 8­bed coronary care unit and 17 high­care beds with continuous 
ECG monitoring. We retrospectively identified all patients who were 
diagnosed with STEMI and admitted to the cardiology ward from 
1 March 2017 to 28 February 2018, and included them in our database.
Design
A retrospective review of case notes was used as research method and 
the following patient characteristics were evaluated:
• age and gender
• primary presenting centre
• cardiovascular risk factors as per discharge summary (hyper­
tension, diabetes mellitus, previous or current cigarette smoking, 
dyslipidaemia, family history of premature coronary disease)
• diagnostic accuracy (whether the diagnosis of STEMI was 
accurate)
• date and time of symptom onset, time of STEMI diagnosis and 
time of administration of a fibrinolytic agent
• success of fibrinolysis in achieving reperfusion (resolution of chest 
pain and reduction in ST­segment elevation by ≥50%)
• survival to hospital discharge
• discharge medication.
Data collection
Tygerberg Hospital’s Enterprise Content Management (ECM) system 
was used to access electronic patient records, including relevant 
ECGs. The National Health Laboratory Service (NHLS) electronic 
platform was used for obtaining laboratory variables. 
Inclusion and exclusion criteria
All patients admitted to Tygerberg Hospital between 1 March 2017 
and 28 February 2018 with an admission or referral diagnosis 
of STEMI were included in the study. Patients with no or 
incomplete clinical case notes on ECM were excluded, as were 
those erroneously entered into the cardiology admissions book as 
cases of STEMI.
Outcome measures
We calculated the time from diagnosis to fibrinolysis in minutes, 
thereby enabling us to directly compare it with the ESC guideline of 
10 minutes.
Secondary prevention forms part of holistic STEMI care. As a 
secondary outcome, we evaluated whether discharge medication was 
appropriate. A discharge script consisting of the following 4 drugs 
was considered to be appropriate:
• angiotensin­converting enzyme (ACE) inhibitor/angiotensin II­receptor 
blocker (ARB)
• beta­blocker
• aspirin
• statin.
Where a clear reason was stated for the omission of any of the 
abovementioned medication, secondary prevention was also noted 
to be appropriate.
Data management and statistical analysis
Data were imported, cleaned and analysed in Microsoft Office, 
version 16.0 (Microsoft, USA) using simple descripive statistics. 
Continious data were presented as either mean and SD or median 
and interquartile range (IQR), depending on data normality, 95% CIs 
were used when appropriate and categorical data were presented 
as frequency and percentages. Normality of data was determined 
graphically. Hypothesis testing with non­parametric tests, such as 
the Mann­Whitney U­test, was used where appropriate. Statistical 
significance was set at p≤0.05.
Ethical approval
This study was approved by the Health Research Ethics Committee, 
Stellenbosch University (ref. no. HREC N18/10/123). Patient 
anonymity was ensured at all times. There were no ethical concerns 
of note.
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Results
Between 1 March 2017 and 28 February 2018, 
492 patients with an admission or referral 
diagnosis of STEMI were identified, of whom 
447 were included in the study (Fig. 2).
The mean age of the population was 56 
(SD 12) years, and the majority of patients 
were male (66.1%; n=299). The diagnosis of 
STEMI was correct in 80.5% (n=360) of the 
population; the other patients were either 
misdiagnosed (4.7%) – most commonly 
patients with a non­STEMI – or the STEMI 
was missed (14.8%).
A total of 240 (53.7%) patients presented 
to a district/provincially funded hospital, 
while only 17 (3.8%) initially presented to 
a tertiary facility. A total of 354 (79.2%) 
patients were either active or ex­cigarette 
smokers. The majority of the population 
(64.9%) had underlying systemic hyper­
tension, while only 13.9% of patients 
admitted to a first­degree relative dying 
of premature cardiovascular disease 
(Table 1).
The median time duration between diag­
nosis and fibrinolysis was 67 (IQR 32.5 ­ 
122.5) min utes, and 18 patients (6.6%; 
95% CI 4.0 ­ 10.3) received fibrinolysis 
within the recommended 10­minute target 
(Fig. 3). The median time between symptom 
onset and fibrinolysis was 270 (IQR 165 ­ 
490) minutes.
There was no significant difference in 
time to fibrinolysis between patients treated 
at public (66 (IQR 30 ­ 130) minutes) v. 
private (69 (IQR 28 ­ 91) minutes) facilities 
(p=0.41)  (Table 2). 
A total of 129 (28.9%) patients did not 
receive fibrinolysis; the reasons are as follows 
(Table 3):
• contraindication to fibrinolysis (7.8%)
• missed STEMI (54.3%)
• spontaneous reperfusion of STEMI (10.1%)
• at Tygerberg Hospital within primary PCI 
window (10.1%).
 
Appropriateness of discharge medication 
was assessed in 360 patients accurately 
diagnosed with STEMI; 301 (83.6%) patients 
were prescribed appropriate secondary 
prevention.
Twenty­three (6.4%) patients correctly 
diagnosed with STEMI died during their 
hospital admission. Of the study population, 
27 (6.0%) patients died during their hospital 
stay.
Discussion
Principal findings 
The primary aim of the study was to evaluate 
whether we are managing patients with 
STEMI adequately. As the median time 
between diagnosis and fibrinolysis was 
67 (IQR 32.5 ­ 122.5) minutes, and only 
18 (5.7%) patients were treated within the 
10­minute target, it is safe to state that we 
are missing the target with some distance. 
A high patient burden and limitations in the 
access to fibrinolytic agents are anecdotally 
some of the challenges of adhering to 
treatment guidelines, but the data presented 
in this article prompt more effort to 
investigate reasons for this significant delay 
in treatment.
The median time interval between symptom 
onset and fibrinolysis was 270 (IQR 165 ­ 
490) minutes. This indicates that the total 
time of ischaemia was at least 4 hours in 
more than half of the patients included in 
the study. The adage of time is muscle holds 
true and suggests that the majority of the 
population studied are subject to significant 
myocardial damage due to the prolonged 
duration of ischaemia.
The majority of patients presented to 
public healthcare facilities, but from the 
abovementioned results we can evaluate 
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Patients with admission or referral diagnosis of STEMI
Patients excluded:
• No or incomplete clinical case notes on ECM
• Incorrect admission/referral diagnosis of STEMI   
Patient information captured on data-collection platform
n=492
n=45
n=447
Fig. 2. Patient recruitment and selection. (STEMI = ST-segment elevation myocardial infarction; 
ECM = Enterprise Content Management.)
Table 1. Demographic information
Results, n (%)*
Age (years), mean (SD) 56 (12)
Sex
Male
Female
299 (66.1)
148 (33.9)
Primary presenting centre
Unknown
Clinic
District/provincially aided hospital
Regional hospital
Tertiary hospital
Private medical facility
52 (11.6)
51 (11.4)
240 (53.7)
53 (11.9)
17 (3.8)
34 (7.6)
Cardiovascular risk factors
Hypertension
Diabetes mellitus
Dyslipidaemia
Smoking history
Family history
290 (64.9)
122 (27.3)
158 (35.3)
354 (79.2)
62 (13.9)
Diagnosis
Correct diagnosis of STEMI
Incorrect diagnosis/diagnoses other than STEMI
360 (80.5)
21 (4.7)
Correct diagnosis of STEMI, but missed 66 (14.8)
SD = standard deviation; STEMI = ST­segment elevation myocardial infarction.
*Unless otherwise specified.
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whether patients referred to Tygerberg Hospital after receiving 
fibrinolysis at private healthcare facilities received treatment more 
timeously. In private healthcare facilities, the median time between 
diagnosis and fibrinolysis was 69 (IQR 18 ­ 91) minutes compared 
with 66 (IQR 33 ­ 130) minutes in public healthcare facilities. This 
difference of 3 minutes (p=0.41) is not statistically significant and 
cannot be interpreted as being accurate of the larger population, as 
the data of only 21 patients were analysed. Nonetheless, it does give 
some indication that the therapeutic delay of STEMI is not only 
limited to public healthcare centres.
Comprehensive management of STEMI not only includes primary 
PCI or fibrinolysis, but also the administration of adequate secondary 
preventive drugs. In a study by Griffiths et al.,[8] the importance of 
secondary preventive measures after acute coronary syndrome is 
outlined, i.e. smoking cessation and administration of a combination 
of 4 drugs: aspirin, beta­blocker, ACE inhibitor or ARB, and a statin. 
In this study, it was found that 71% of patients were discharged on 
the appropriate medication regimen, while only 48% were taking the 
medication at their 6­month follow­up visit. This serves as a reminder 
that not only does emergency treatment of STEMI reduce the 
disease burden caused by IHD, but that emphasis is required on the 
importance of secondary prevention and longer­term management. 
At discharge from Tygerberg Hospital, 301 (83.6%) patients correctly 
diagnosed with STEMI received adequate discharge medication.
With regard to the abovementioned primary and secondary 
outcomes, one can conclude that more emphasis should be placed 
on timeous treatment of STEMI in healthcare centres prior to 
referral to cardiac units, given the inevitable delays in transportation 
of patients. Medical personnel should familiarise themselves with 
early recognition of symptoms, accurate diagnosis and appropriate 
management of acute STEMI to improve management of IHD. By 
reducing the delay in treatment, we can reduce the burden of IHD on 
the individual and on the greater healthcare system in SA.
Study strengths and limitations
The data presented in this article are comprehensive with regard to 
the population size, geographical involvement of the drainage area of 
a tertiary referral centre and inclusion of patients diagnosed over 
12 months. This information enabled us to accurately analyse STEMI 
treatment in the involved facilities and allows extrapolation of results 
to the Western Cape and the greater SA.
Further data from the private healthcare sector are needed to 
comment with more certainty on the correlation between treatment 
times in public and private healthcare facilities. The study findings 
must be seen in view of the limited data, but still offer some 
interesting results.
Lastly, there is a discrepancy in the guidelines set by the ESC and 
the American Heart Association/American College of Cardiology 
(AHA/ACC) in that the latter recommends fibrinolysis within 30 minutes 
of diagnosis of STEMI,[9] as opposed to the ESC’s guideline of 10 minutes. 
The AHA/ACC guideline moves the target significantly closer to the 
results obtained in this study.
Table 2. Results of therapeutic interventions
Median (IQR), min†
Patients who received fibrinolysis, n (%)
Documented time to fibrinolysis
≤10 
11 ­ 30
31 ­ 60
61 ­ 240
>240 
Undocumented time to fibrinolysis
Successful fibrinolysis, n (%)
318 (71.1)
271 (85.2)
18 (6.6)
46 (17.0)
67 (24.7)
115 (42.4)
25 (9.2)
47 (14.8)
234 (73.6)
Time interval
 Between diagnosis and fibrinolysis in all 
centres
67 (32.5 ­ 122.5)
 Between symptom onset and fibrinolysis 270 (165 ­ 490)
 Between diagnosis and fibrinolysis in 
private centres
69 (28 ­ 91)
 Between diagnosis and fibrinolysis in 
public centres
66 (33 ­ 130)
 Difference between patients in private 
and public centres
3*
IQR = interquartile range.
*p=0.41.
†Unless otherwise specified.
Table 3. Discharge information
Results, n (%)
Discharge medication 
Appropriate discharge medication
Inappropriate discharge medication
Deceased
301 (83.6)
59 (10.3)
23 (6.3)
Aspirin 
Prescribed appropriately
Omitted without reason
Contraindicated
382 (95.7)
15 (3.8)
2 (0.5)
Statin 
Prescribed appropriately
Omitted without reason
Contraindicated
376 (94.2)
23 (5.8)
0 (0)
ACE inhibitor/ARB 
Prescribed appropriately
Omitted without reason
Contraindicated
384 (96.2)
13 (3.3)
2 (0.5)
Beta­blocker 
Prescribed appropriately
Omitted without reason
Contraindicated
379 (95.0)
17 (4.3)
3 (0.8)
Mortality 
Overall study population
Patients correctly diagnosed with STEMI
27 (6.0)
23 (6.4)
ACE = angiotensin­converting enzyme; ARB = angiotensin II­receptor blocker;  
STEMI = ST­segment elevation myocardial infarction.
42%
≤10 min
11 - 30 min
31 - 60 min
61 - 240 min
>240 min
9% 7%
17%
25%
Fig. 3. Patients receiving fibrinolysis – time intervals.
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Unanswered questions and recommendations for future 
studies
The results of this study are useful, as they enable evaluating whether 
the involved healthcare facility adheres to treatment guidelines. 
There are multiple factors that influence the therapeutic delay 
between diagnosis and treatment, and without this knowledge one 
cannot address the problems identified. To improve the treatment of 
STEMI, it will therefore be interesting and invaluable to know what 
modifiable factors are involved in prolonging the duration between 
diagnosis and fibrinolysis. 
Conclusions
Knowing that IHD is a major contributor to mortality in the Western 
Cape and the greater SA, it is becoming more important to treat 
patients presenting with acute STEMI effectively. In centres within 
the drainage area of Tygerberg Hospital, we found that the median 
duration between diagnosis of STEMI and fibrinolysis was 67 (IQR 32.5 
­ 122.5) minutes. This is in contrast to the treatment guideline 
of 10 min utes of the ESC. It is therefore imperative that factors 
affecting treatment delay be investigated and addressed to improve 
patient outcomes and decrease the burden of IHD on the healthcare 
system of SA.
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